A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Recruiting
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
11/16/2023
Locations: Hattiesburg Clinic, PA, Hattiesburg, Mississippi
Conditions: Alzheimer's Disease
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
11/06/2023
Locations: Hattiesburg Clinic, Hattiesburg, Mississippi
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
Recruiting
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
11/01/2023
Locations: Hattiesburg Clinic, Hattiesburg, Mississippi
Conditions: Alzheimer's Disease
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
10/16/2023
Locations: Prime Health and Wellness/SKYCRNG, Fayette, Mississippi +1 locations
Conditions: Alzheimer Disease